1. Cohen, MH, Williams, G, Johnson, JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8: 935–942.
Google Scholar | Medline | ISI2. Cortes, JE, Saglio, G, Kantarjian, HM, et al. Final 5 year study results of DASISION: the dasatinib versus imatinib study in treatment naive chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.
Google Scholar | Crossref | Medline | ISI3. Hochhaus, A, Saglio, G, Hughes, TP, et al. Long term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5 year update of the randomized ENESTnd trial. Leukemia 2016; 30: 1044–1054.
Google Scholar | Crossref | Medline | ISI4. Deininger, MW, Kota, V, Lipton, JH, et al. Bosutinib or imatinib in older vs younger patients with newly diagnosed chronic myeloid leukemia in the phase 3 BFORE trial. Blood 2018; 132: 1734–1734.
Google Scholar | Crossref | Medline5. Cortes, JE, Kim, DW, Pinilla Ibarz, J, et al. Ponatinib efficacy and safety in Philadelphia chromosome positive leukemia: final 5 year results of the phase 2 PACE trial. Blood 2018; 132: 393–404.
Google Scholar | Crossref | Medline6. Cortes, JE. A second generation TKI should always be used as initial therapy for CML. Blood Adv 2018; 2: 3653–3655.
Google Scholar | Crossref | Medline7. Cortes, J, Kantarjian, H. Chronic myeloid leukemia: sequencing of TKI therapies. Hematology Am Soc Hematol Educ Program 2016; 2016: 164–169.
Google Scholar | Crossref | Medline8. Shallis, RM, Wang, R, Davidoff, A, et al. Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map. Blood Rev 2020; 42: 100706.
Google Scholar | Crossref | Medline9. Shallis, RM, Podoltsev, N. What is the best pharmacotherapeutic strategy for treating chronic myeloid leukemia in the elderly. Expert Opin Pharmacother 2019; 20: 1169–1173.
Google Scholar | Crossref | Medline10. Henk, HJ, Woloj, M, Shapiro, M, et al. Real world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States. Clin Ther 2015; 37: 124–133.
Google Scholar | Crossref | Medline11. Rashid, N, Koh, HA, Lin, KJ, et al. Real world treatment patterns in chronic myeloid leukemia patients newly initiated on tyrosine kinase inhibitors in an U.S. integrated healthcare system. J Oncol Pharm Pract 2018; 24: 253–263.
Google Scholar | SAGE Journals | ISI12. Banegas, MP, Rivera, DR, O’Keeffe Rosetti, MC, et al. Long term patterns of oral anticancer agent adoption, duration, and switching in patients with CML. J Natl Compr Canc Netw 2019; 17: 1166–1172.
Google Scholar | Crossref | Medline13. Cortes, J. How to manage CML patients with comorbidities. Blood 2020; 136: 2507–2512.
Google Scholar | Crossref | Medline14. Rivera, DR, Enewold, L, Barrett, MJ, et al. Population based utilization and costs associated with tyrosine kinase inhibitors for first line treatment of chronic myelogenous leukemia among elderly patients. J Manag Care Spec Pharm 2020; 26: 1494–1504.
Google Scholar | Medline15. Di Bella, NJ, Bhowmik, D, Bhor, M, et al. The effectiveness of tyrosine kinase inhibitors and molecular monitoring patterns in newly diagnosed patients with chronic myeloid leukemia in the community setting. Clin Lymphoma Myeloma Leuk 2015; 15: 599–605.
Google Scholar | Crossref | Medline16. Geelen, IGP, Thielen, N, Janssen, J, et al. Treatment outcome in a population based, ‘real world’ cohort of patients with chronic myeloid leukemia. Haematologica 2017; 102: 1842–1849.
Google Scholar | Crossref | Medline17. Jabbour, E, Kantarjian, H, Cortes, J. Use of second and third generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015; 15: 323–334.
Google Scholar | Crossref | Medline | ISI18. Specchia, G, Pregno, P, Nicolosi, M, et al. Chronic myeloid leukemia Italian multicenter observational study (CML IT MOS): clinical characteristics of chronic myeloid leukemia (CML) patients treated in real life between 2012 and 2016 in 66 Italian hematology centers of the gimema study group. Blood 2018; 132: 45–45.
Google Scholar | Crossref19. Hehlmann, R, Cortes, JE, Zyczynski, T, et al. Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY. Am J Hematol 2019; 94: 46–54.
Google Scholar | Crossref | Medline20. Enewold, L, Parsons, H, Zhao, L, et al. Updated overview of the SEER Medicare data: enhanced content and applications. J Natl Cancer Inst Monogr 2020; 2020: 3–13.
Google Scholar | Medline21. Wassie, EA, Itzykson, R, Lasho, TL, et al. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic French Consortium Study. Am J Hematol 2014; 89: 1111–1115.
Google Scholar | Crossref | Medline22. Hollenbeck, BK, Ye, Z, Dunn, RL, et al. Provider treatment intensity and outcomes for patients with early stage bladder cancer. J Natl Cancer Inst 2009; 101: 571–580.
Google Scholar | Crossref | Medline23. Healy, MA, Yin, HY, Reddy, RM, et al. Use of positron emission tomography to detect recurrence and associations with survival in patients with lung and esophageal cancers. J Natl Cancer Inst 2016; 108: djv429.
Google Scholar | Crossref | Medline24. Gupta, A, Long, JB, Chen, J, et al. Risk of vascular toxicity with platinum based chemotherapy in elderly patients with bladder cancer. J Urol 2016; 195: 33–40.
Google Scholar | Crossref | Medline25. Klabunde, CN, Potosky, AL, Legler, JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258–1267.
Google Scholar | Crossref | Medline | ISI26. Elixhauser, A, Steiner, C, Harris, DR, et al. Comorbidity measures for use with administrative data. Med Care 1998; 36: 8–27.
Google Scholar | Crossref | Medline | ISI27. Jabbour, E, Makenbaeva, D, Lingohr Smith, M, et al. Use of real world claim databases to assess prevalence of comorbid conditions relevant to the treatment of chronic myelogenous leukemia based on national comprehensive network treatment guidelines. Clin Lymphoma Myeloma Leuk 2015; 15: 797–802.
Google Scholar | Crossref | Medline | ISI28. Kantarjian, H, Shah, NP, Hochhaus, A, et al. Dasatinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.
Google Scholar | Crossref | Medline | ISI29. Hochhaus, A, Larson, RA, Guilhot, F, et al. Long term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017; 376: 917–927.
Google Scholar | Crossref | Medline | ISI30. Lipton, JH, Chuah, C, Guerci Bresler, A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open label, phase 3 trial. Lancet Oncol 2016; 17: 612–621.
Google Scholar | Crossref | Medline31. Latagliata, R, Breccia, M, Carmosino, I, et al. “Real life” results of front line treatment with Imatinib in older patients (>/= 65 years) with newly diagnosed chronic myelogenous leukemia. Leuk Res 2010; 34: 1472–1475.
Google Scholar | Crossref | Medline | ISI32. Latagliata, R, Stagno, F, Annunziata, M, et al. Frontline dasatinib treatment in a “Real Life” cohort of patients older than 65 years with chronic myeloid leukemia. Neoplasia 2016; 18: 536–540.
Google Scholar | Crossref | Medline33. Chanfreau, C, Lynch, KE, Chang, J, et al. Chronic myeloid leukemia among veterans from 2006 2015: trends in utilization of tyrosine kinase inhibitors 2018; 36: e18832.
Google Scholar | Crossref34. Winn, AN, Keating, NL, Dusetzina, SB. Factors associated with tyrosine kinase inhibitor initiation and adherence among Medicare beneficiaries with chronic myeloid leukemia. J Clin Oncol 2016; 34: 4323–4328.
Google Scholar | Crossref | Medline35. Blustein, J, Weiss, LJ. Visits to specialists under Medicare: socioeconomic advantage and access to care. J Health Care Poor Underserved 1998; 9: 153–169.
Google Scholar | Crossref | Medline | ISI36. Shah, BK, Uprety, D. Racial differences in survival of elderly adults with chronic myeloid leukemia before and after the introduction of imatinib in the United States. J Am Geriatr Soc 2016; 64: 887–889.
Google Scholar | Crossref | Medline